Olink

Olink®
Part of Thermo Fisher Scientific

Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia

Nature Communications, 2022

Huuhtanen J., Bhattacharya D., Lönnberg T., Kankainen M., Kerr C., Theodoropoulos J., Rajala H., Gurnari C., Kasanen T., Braun T., Teramo A., Zambello R., Herling M., Ishida F., Kawakami T., Salmi M., Loughran T., Maciejewski J., Lähdesmäki H., Kelkka T., Mustjoki S.

Disease areaApplication areaSample typeProducts
Oncology
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

T cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder of mature, clonally expanded T cells, where somatic-activating STAT3 mutations are common. Although T-LGLL has been described as a chronic T cell response to an antigen, the function of the non-leukemic immune system in this response is largely uncharacterized. Here, by utilizing single-cell RNA and T cell receptor profiling (scRNA+TCRαβ-seq), we show that irrespective of STAT3 mutation status, T-LGLL clonotypes are more cytotoxic and exhausted than healthy reactive clonotypes. In addition, T-LGLL clonotypes show more active cell communication than reactive clones with non-leukemic immune cells via costimulatory cell–cell interactions, monocyte-secreted proinflammatory cytokines, and T-LGLL-clone-secreted IFNγ. Besides the leukemic repertoire, the non-leukemic T cell repertoire in T-LGLL is also more mature, cytotoxic, and clonally restricted than in other cancers and autoimmune disorders. Finally, 72% of the leukemic T-LGLL clonotypes share T cell receptor similarities with their non-leukemic repertoire, linking the leukemic and non-leukemic repertoires together via possible common target antigens. Our results provide a rationale to prioritize therapies that target the entire immune repertoire and not only the T-LGLL clonotype.

Read publication ↗